Project Grant R21HL184196
- Federal Grant Award Summary Cincinnati Children's Hospital Medical Center received a $1,429,215 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective June 1, 2025, through March 31, 2029. The award supports basic and translational research investigating MEOX2 as a critical regulator of alveolar fibroblast function and its role in lung development and disease. The research aims to elucidate molecular...
- Federal Grant Award Summary Cincinnati Children's Hospital Medical Center received a $249,000 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded April 2, 2026, with completion targeted for March 31, 2029. The research project, titled "Frontiers at the Edge: Subpleural Fibroblasts Orchestrate Pulmonary Fibrosis Progression," supports basic and translational research investigating the...
- Federal Project Grant Award Summary Cincinnati Children's Hospital Medical Center received a $511,987 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 27, 2025, with a completion date of May 31, 2029. The award funds a comparative mechanistic study of lamin-related cardiomyopathy (LMNA-related dilated cardiomyopathy), specifically investigating two prevailing hypotheses regarding...
- Federal Grant Award Summary Cincinnati Children's Hospital Medical Center received a $727,575 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 15, 2025, with completion targeted for May 31, 2030. The project will investigate the cellular mechanisms and clinical impact of the genetic variant rs7512462 within the SLC26A9 gene on individual patient responses to cystic fibrosis (CF)...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Children's Hospital of Philadelphia Research Institute a $594,583 Project Grant effective August 10, 2025, through May 31, 2029, under the Cardiovascular Diseases Research program (CFDA 93.837). This research project, titled "Origins of Neonatal Lung Myofibroblasts," focuses on advancing understanding of myofibroblast development and function during neonatal lung maturation. The research...
- Federal Project Grant Award Summary Cincinnati Children's Hospital Medical Center received a $169,352 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective June 16, 2025, with completion targeted for December 21, 2027. This award funds research aimed at characterizing NRAC (Nutritionally Regulated Adipose and Cardiac-Enriched Gene), a novel microprotein involved in lipid droplet biogenesis and...
- Federal Project Grant Award Summary Cincinnati Children's Hospital Medical Center received a $441,375 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded August 15, 2025, with a completion date of July 31, 2027. The grant supports research to develop and optimize a novel dual adenoassociated virus (AAV) gene delivery system utilizing intein technology to deliver full-length, functional cystic...
- Federal Project Grant Award Summary Boston Children's Hospital received a $809,162 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 15, 2025, with a completion date of June 30, 2030. The award funds research investigating pulmonary ionocyte function and development using human induced pluripotent stem cell (iPSC)-derived airway epithelium models. The research aims to elucidate ionocyte...
- Federal Grant Award Summary Cincinnati Children's Hospital Medical Center received a $731,130 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded September 19, 2025, with completion targeted for June 30, 2030. The award supports a multi-site, two-stage Sequential Multiple Assignment Randomized Trial (SMART) designed to evaluate the effectiveness of an adaptive mobile health (mHealth) intervention for...
- Federal Project Grant Award Summary Cincinnati Children's Hospital Medical Center received a $249,000 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 25, 2025, with completion targeted for July 31, 2028. The award supports research investigating the molecular mechanisms linking the transcription factor PITX2 (Pituitary Homeobox 2) to atrial fibrillation (AF) risk through...
Cincinnati Children's Hospital Medical Center received a $120,375 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective April 15, 2026, with completion anticipated by January 31, 2028. The award supports the development of FLUME (Fetal Lung Multiomics Exploration), a human fetal lung multiomics cell atlas with computational models designed to predict fetal origins and molecular perturbations associated with childhood interstitial lung diseases (CHILD). Through secondary analysis of existing large-scale single-cell multiomics and spatial transcriptomics datasets of human fetal lung tissue, the research will identify specific fetal lung cell states and genes that, when disrupted, produce cellular and molecular phenotypes consistent with CHILD caused by variants in genes such as FOXF1 and TBX4. The project addresses a critical knowledge gap regarding early disruptions in fetal lung development and the mechanistic basis of rare but severe respiratory disorders in neonates and infants. By leveraging previously published datasets rather than generating new primary data, the award focuses on computational and analytical work to create predictive models that can enhance understanding of how genetic perturbations during critical developmental windows lead to postnatal lung disease manifestations, with potential implications for improving diagnosis, prognosis, and therapeutic intervention strategies in pediatric pulmonary disorders.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $120.4k | 4/8/26 |